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Abstract. A characteristic of the epithelial-to-mesenchymal 
transition in cancer cells is the upregulation of mesenchymal 
markers. Fibroblast activation protein α (FAPα) is predomi-
nantly expressed by stromal fibroblasts. Previous studies 
have demonstrated that FAPα is also expressed by certain 
epithelium-derived cancer cells and is involved in the regula-
tion of certain signaling pathways. One of our previous studies 
showed that FAPα promoted the proliferation of breast cancer 
cells via the phosphatidylinositol-3-kinase (PI3K) signaling pathway. In the present study, the A549 adenocarcinoma (AC) 
and SK-MES-1 squamous cell carcinoma (SCC) lung cancer 
cell lines were transfected with FAPα. The FAPα-expressing SK-MES-1 cells exhibited an increased growth rate, 
whereas the FAPα-expressing A549 cells exhibited a similar growth rate, compared with respective empty vector-trans-
fected control cells. Electric cell-substrate impedance 
sensing (ECIS)-based attachment and wound-healing assays 
showed that the overexpression of FAPα markedly increased 
the adhesive and migratory properties of the SK-MES-1 cells but not those of the A549 cells. Additionally, inhibitors of focal adhesion kinase, agonist-induced phospholipase C, neural Wiskott-Aldrich syndrome protein, extracellular signal-regu-lated kinase, Rho-associated protein kinase, PI3K, and sonic 
hedgehog (SHH) were used to evaluate the interaction between 
FAPα and signaling pathways. Only the inhibitors of SHH and 
PI3K inhibited the increased motility of the FAPα-expressing SK-MES-1 cells. Western blot analysis conirmed the activation of PI3K/AKT and SHH/GLI family zinc inger 1 signaling in 
the FAPα-expressing SK-MES-1 cells. These results revealed 
that FAPα promoted the growth, adhesion and migration of lung SCC cells. In addition, FAPα regulated lung cancer cell function, potentially via the PI3K and SHH pathways. Further 
investigations are required to examine the role of FAPα in 
lung AC cells.
Introduction
The epithelial-to-mesenchymal transition (EMT) is a compli-
cated and critical process in the metastatic spread of cancer 
cells. The transition of morphology of a cancer cell from an 
epithelial to a mesenchymal morphology leads to increased 
migratory and invasive cellular properties. Previous studies 
have demonstrated that EMT in cancer cells involves the 
upregulation of mesenchymal markers and the downregula-tion of epithelial cell markers (1,2). For example, ibroblast speciic protein-1 (S100A4) is a prototypical ibroblast marker 
of EMT in cancer; the expression of S100A4 is associated with 
cellular motility and the regulation of cell polarization through its effects on the localization of protrusions, which involves interactions with myosin-IIA (1,3). The α-smooth muscle 
actin (αSMA) protein is expressed by vascular smooth muscle and myoepithelial cells, and is also considered a marker of 
EMT. There is also evidence that type 3 EMT is associated 
with αSMA in basal-like breast cancer (2,4). Therefore, the 
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function of these molecules expressed by stromal ibroblasts 
and epithelium-derived cancer cells may be importance in 
EMT.
Fibroblast activation protein-α (FAPα) is an integral 
membrane serine peptidase. Previous studies have shown that 
FAPα is expressed primarily in fetal mesenchymal tissues, stromal ibroblasts, wounded tissues and stromal ibroblasts of malignant epithelial tumors (5-7). FAPα expressed by stromal cancer-associated ibroblasts has dipeptidyl peptidase activity (8,9) and collagenolytic activity (10,11). By degrading the extracellular matrix, FAPα promotes the growth and 
metastasis of cancer cells (12-14). The overexpression of 
FAPα is also associated with distant metastasis, tumor recur-rence and poor survival rates (15,16). In addition, previous 
studies have shown that FAPα is expressed in certain types of epithelium-derived cancer, including breast (17), gastric (18), esophageal (19), ovarian (20) and colorectal cancer (21).
The functions of cancer cell-expressed FAPα have been 
investigated in a number of studies and the results from these 
suggest that FAPα has a non-enzymatic function. Wang et al 
analyzed the effect of the overexpression of FAPα on the LX-2 human hepatic stellate cell line (22); it was found that 
the overexpression of FAPα increased the adhesion, migration and invasion of LX-2 cells, and that the proteolytic activity of 
FAPα was not necessary for these functions (22). Huang et al used two inhibitors, PT-630 and LAF-237, to inhibit the 
dipeptidyl peptidase activity of FAPα (23), and found that 
the inhibitors were unable to slow the growth of tumors in 
severe combined immunodeficient (SCID) mice implanted 
with FAPα-expressing breast cancer WTY-1/6 cells (MDA 
MB-231 cells transfected with FAPα) and MDA-MB-435 cells 
(endogenously express FAPα). In addition, breast cancer cells 
expressing a catalytically inactive mutant of FAPα produced tumors, which grew rapidly (23). Wang et al found that the 
knockdown of FAPα in oral squamous cancer cells suppressed 
cell proliferation in vitro and inhibited the growth of tumor 
xenografts in mice in vivo. Notably, suppressing FAPα in oral 
squamous cancer cells significantly decreased the expres-sion of phosphorylated phosphatidylinositol-3-kinase (PI3K), protein kinase B (AKT), mitogen-activated protein kinase kinase 1/2 and extracellular signal-regulated kinase (ERK)1/2, 
and upregulated the expression of phosphatase and tensin homolog (PTEN) (24). In our previous study (25), the over-
expression of wild-type FAPα and the enzymatic mutant FAPS624A, in which the serine catalytic triad was disrupted, markedly increased cellular growth and motility in MCF-7 
breast cancer cells. These observations were consistent 
with those for FAPα-silenced BT549 breast cancer cells. 
Western blot analysis also revealed that the overexpression 
of wild-type FAPα and the enzymatic mutant FAPS624A 
resulted in the activation of PI3K/AKT and matrix metallopro-teinase 2/9 (MMP2/9) (25). These results suggested that FAPα 
may serve as an oncogene and be involved in the regulation of 
cell signaling pathways.Therefore, the present study analyzed the function of FAPα 
in lung cancer cells in order to examine its non-enzymatic function. It was hypothesized that, as a membrane protein, 
FAPα may be involved in the regulation of certain signaling pathways and, through this mechanism, exert its effect on lung 
cancer cells.
Materials and methods
Materials and cell lines. The SK-MES-1 squamous cell carci-noma (SCC) and A549 adenocarcinoma (AC) human lung 
cancer cell lines were obtained from the American Type Culture Collection (Manassas, VA, USA). Primary antibodies against 
human FAPα (cat. no. AF3715) were from R&D Systems, Inc. (Minneapolis, MN, USA). Primary antibodies against glyceral-
dehyde 3-phosphate dehydrogenase (GAPDH; cat. no. sc-32233) and an inhibitor (Y-27632; cat. no. sc-3536) of Rho-associated protein kinase (ROCK) were from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). The focal adhesion kinase (FAK) inhibitor (cat. no. 3414) was from Tocris Bioscience (Bristol, UK). The ERK1/2 inhibitor (FR180204, cat. no. 328007), 
phospholipase C-γ (PLCγ) inhibitor (U73122, cat. no. 662035), 
neural Wiskott-Aldrich syndrome protein (NWASP) inhibitor (wiskostatin, cat. no. 681525), PI3K inhibitor (wortmannin, cat. no. 681675), c-Jun N-terminal kinase (JNK) inhibitor (SP600125, cat. no. 420119), sonic hedgehog (SHH) inhibitor (cyclopamine, cat. no. 239803) and a negative control of cyclo-pamine (tomatidine, cat. no. 614350) were from Calbiochem; Merck Millipore (Darmstadt, Germany). Matrigel (reconsti-
tuted basement membrane) was purchased from Collaborative Biomedical Products, Inc. (Bedford, MA, USA). Transwell 
plates equipped with a porous insert (8-µm pore size) were from BD Biosciences (Franklin Lakes, NJ, USA). Reverse transcrip-
tion-polymerase chain reaction (RT-PCR) reagents and plasmid extraction kits were from Sigma-Aldrich, Inc. (St. Louis, MO, USA). Antibodies against human PI3K (cat. no. ab22653), AKT (cat. no. ab8805), SHH (cat. no. ab53281), Patched (Ptch; cat. no. ab53715), and GLI family zinc inger 1 (Gli1; cat. no. ab151796) were from Abcam PLC (Cambridge, UK).
Construction of FAPα-expressing lung cancer cell lines. 
The cDNA of FAPα (NM_004460) was inserted into a pEF6/V5-His vector (Invitrogen; Thermo Fisher Scientiic, Inc., Waltham, MA, USA) and maintained at -80˚C in the Laboratory of Carcinogenesis and Translational Research, Peking University Cancer Hospital and Institute, as described in our previous study (25). The SK-MES-1 and A549 lung cancer cells were cultured in DMEM/F12 media at 37˚C with 5% CO2. The cells were transfected with the pEF6/V5-FAPα 
plasmid by electroporation. Following the selection of trans-fected cells with blasticidin S (5 µg/ml) and veriication via RT-PCR analysis (RT-reaction: annealing at 65˚C for 5 min, extension at 55˚C for 20 min, inactivation at 75˚C for 15 min. PCR reaction: initial denaturation at 94˚C for 5 min; then denaturation at 94˚C for 30 sec, annealing at 55˚C for 30 sec, extension at 72˚C for 1 min in each cycle for totally 25 cycles, followed by a inal extension of 10 min at 72˚C), the following 
stably transfected cells were established: FAPα-overexpressing cells (SK-MES-1exp and A549exp), plasmid vector-transfected control cells (SK-MES-1pef and A549pef), and wild-type cells (SK-MES-1wt and A549wt). The transfected cells were continually cultured in a maintenance medium, which contained 0.5 µg/ml blasticidin S.
In vitro growth, adhesion and invasion assays. For the growth assay, the cells were plated into a 96-well plate at a density of 2,000 cells/well (n=12) followed by a period of incubation. 
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The cells were either ixed in 10% formaldehyde on the day of plating or 3 days later. Crystal violet (0.5% w/v) was used to stain the cells. Subsequently, the crystal violet was dissolved with 10% (v/v) acetic acid and the absorbance of cells, which represented the cell number, was determined at a wavelength of 540 nm.For the adhesion assay, a 96-well plate was pre-coated with 5 µg of Matrigel and left to dry overnight. Following rehydra-tion with serum-free media, 1,500 cells were seeded into each well (n=6). Following incubation for 60 min, the non-adherent 
cells were washed off using BSS buffer. The remaining cells were ixed with 4% formalin and stained with 0.5% crystal 
violet. The numbers of adherent cells were then counted under an Olympus CX31 microscope.For the invasion assay, Transwell inserts with a 8-µm pore size were coated with 50 µg of Matrigel and air-dried. Following rehydration with serum-free media, the cells were seeded at a density of 30,000 cells/insert (n=5). After 3 days of incubation at 37˚C with 5% CO2, the cells, which had migrated 
through the matrix and adhered to the other side of the insert were ixed in 4% formalin, stained with 0.5% (w/v) crystal violet, and counted under a microscope.
Electric cell-substrate impedance sensing (ECIS)-based 
cell attachment and migration assay. An ECIS instrument (Applied BioPhysics, Inc., Troy, NY, USA) was used to record the adhesive and migratory abilities of the cells, which were 
determined from the changes in the impedance of cells. 96W1E arrays were incubated with complete medium for 1 h, following which 50,000 lung cancer cells were seeded into each well (n=16). Electrical changes were continuously moni-tored for up to 24 h, with electrical wounding performed at 6 h. Multiple frequencies (1,000, 2,000, 4,000 and 8,000 Hz) were 
used to assess the nature of changes in resistance.
Inhibition of signaling pathways with inhibitors. In order to 
examine the potential crosstalk between FAPα and adhesion and migration-associated signaling pathways, inhibitors of FAK, ERK1/2, ROCK, PLCγ, JNK, NWASP, PI3K and SHH 
were used in an ECIS-based cell function assay. A total of 50,000 cells were suspended in 200 µl DMEM with inhibi-tors of FAK, ERK1/2, ROCK, PLCγ, NWASP, JNK, PI3K and SHH, respectively, to a inal concentration of 100 nM. Changes in electrical resistance under multiple frequencies (1,000, 2,000, 4,000 and 8,000 Hz) were continuously monitored for up to 24 h, with electrical wounding performed at 6 h in the ECIS-based wounding assay (n=8).
Western blot analysis. Western blot analysis was performed to 
detect the expression of FAPα and other downstream signaling 
pathway molecules in the transfected SK-MES-1 lung cancer cells and control cells. The conluent cells were pelleted and then lysed in lysis buffer containing 2.4 mg/ml Tris, 4.4 mg/ml NaCl, 5 mg/ml sodium deoxycholate, 20 µg/ml sodium azide, 1.5% Triton X-100, 100 µg/ml phenylmethylsulfonyl luoride, 1 µg/ml leupeptin and 1 µg/ml aprotinin, for 45 min at 4˚C. Following lysis and centrifugation at 10,000 x g for 15 min at 4˚C, the isolated proteins were diluted in sample buffer and the 
concentration of each sample was measured using an improved Lowry assay (DC protein assay kit; Bio-Rad Laboratories, 
Inc., Hercules, CA, USA). The samples were adjusted to equal 
concentrations (2 mg/ml) with sample buffer and then boiled at 100˚C for 5 min prior to separation on a 10% polyacryl-amide gel. Following electrophoresis, the separated protein 
samples were transferred onto polyvinylidenedifluoride membranes (EMD Millipore, Billerica, MA, USA) and incubated at 4˚C overnight with primary antibodies against 
FAPα, PI3K, AKT, SHH, Ptch, Gli1 and GAPDH at a dilution of 1:200. The membranes were then incubated with speciic peroxidase-conjugated secondary antibodies (cat. nos. sc-2357 or sc-2031; Santa Cruz Biotechnology, Inc.) at a dilution of 1:1,000 for 40 min at room temperature. The protein signals 
were detected using an enhanced chemiluminescence system (Pierce; Thermo Fisher Scientiic, Inc.).
Statistical analysis. All results are expressed as the mean ± stan-
dard error of the mean. One-way analysis of variance and an 
independent samples t-test were used to evaluate the differences between groups in all the assays performed, with the resultant P-values representing two-sided tests of statistical signiicance. All statistical analyses were performed using SPSS 17.0 soft-ware (SPSS, Inc., Chicago, IL, USA). P<0.05 was considered to indicate a statistically signiicant difference.
Results
Expression of FAPα in lung cancer cells. To identify the 
oncogenic function of FAPα in lung cancer cells, FAPα was 
transfected into the FAPα-null SK-MES-1 and A549 lung 
cancer cell lines. RT-PCR and western blot analyses were used to conirm the expression of FAPα in the transfected cells. The 
overexpression of FAPα in the SK-MES-1 and A549 cells was 
successfully established (Fig. 1).
Overexpression of FAPα promotes the growth of SK-MES-1 
cells. The present study irst examined the effect of the overex-
pression of FAPα on cellular growth in vitro. Compared with the SK-MES-1wt cells, the overexpression of FAPα signii-
cantly increased the growth rate of the SK-MES-1exp cells at 3 days post-seeding (n=12; 575.5±171.9 vs. 793.6±140.1%, respectively; P=0.003), which was also signiicantly higher, 
compared with that of the SK-MES-1pef cells (611.6±181.8; P=0.012). By contrast, the growth rate of the A549exp cells (357.5±74.2%) was similar to the growth rates of the A549wt cells (370.6±83.2; n=12; P=0.686) and A549pef cells (357.8±57.4%, P=0.989) at 3 days post-seeding (Fig. 2).
Overexpression of FAPα increases the attachment of SK-MES-1 
cells to basement membrane proteins. In a matrix gel-based adhe-sion assay, compared with the control cells, FAPα-expressing SK-MES-1exp and A549exp cells showed increased adhesion to the matrix gel 1 h following seeding; however, no statisti-cally signiicant differences were found between the groups of SK-MES cells (n=6; SK-MES-1wt vs. SK-MES-1exp, 25±14.4 vs. 37.3±19.9; P=0.246; SK-MES-1pef vs. SK-MES-1exp, 31.7±10.3 vs. 37.3±19.9; P=0.549) or A549 cells (A549wt vs. A549exp, 17.7±15.7 vs. 24.5±12.3; P=0.422; A549pef vs. A549exp, 14.5±14.4 vs. 24.5±12.3, P=0.225) (Fig. 3A and B). To conirm the results of the matrix gel-based adhesion assay, 
an ECIS-based cell function assay was performed as a more 
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sensitive and accurate assessment. In the irst phase post-cell seeding, increased impedance relects the ability of cells to adhere to the substrate; the faster the impedance increases, the 
higher the rate of cell attachment to the substrate. In the present study, compared with the SK-MES-1wt and SK-MES-1pef control cells, the FAPα-expressing SK-MES-1exp cells showed increased attachment at 1 h post-seeding (n=12; SK-MES-1wt vs. SK-MES-1exp, 343.1±135.3 vs. 948.3±442.7 ohms; P=0.001; SK-MES-1pef vs. SK-MES-1exp, 566.3±321.0 vs. 948.3±442.7 ohms; P=0.037). However, in the A549 cells, the vector-trans-fected A549pef cells showed the highest attachment ability, whereas the A549exp cells and A549wt cells exhibited similar attachment abilities (n=12; A549wt vs. A549exp, 234.1±149.4 vs. 292.2±191.0 ohms; P=0.416; A549pef vs. A549exp, 497.7±184.5 vs. 292.2±191.0 ohms; P=0.014) (Fig. 3C-E).
Overexpression of FAPα does not promote the invasion of lung 
cancer cells. To analyze the effect of the overexpression of FAPα on the invasion of lung cancer cells, the present study performed 
an in vitro matrix gel-based invasion assay. Although FAPα has dipeptidyl peptidase and collagenolytic activities, the results 
showed that the overexpression of FAPα did not increase the invasive ability of either SK-MES-1 or A549 cells. By contrast, 
the number of invaded cells in the FAPα-expressing SK-MES-1 cell group on day 3 was lower, compared with that in the wild-type and vector-transfected control cell groups; however, no signiicant differences were observed between the groups (n=5; SK-MES-1wt vs. SK-MES-1exp, 184.2±77.8 vs. 110.4±11.4; P=0.138; SK-MES-1pef vs. SK-MES-1exp, 126.0±13.2 vs. 110.4±11.4; P=0.081). In the A549 cells, the number of invaded 
cells in the FAPα-expressing A549exp cell group on day 3 was similar to that in the A549wt cell group (n=5; 37.8±15.4 vs. 42.0±6.5, respectively; P=0.59), but less than that in the A549pef group (88.8±17.9 vs. 37.8±15.4; P=0.001) (Fig. 4).
Overexpression of FAPα increases the migration of SK-MES-1 
cells. To investigate the effect of FAPα on the migration of lung cancer cells, the more accurate ECIS-based wounding assay was 
used rather than a physical scratch-wound assay. In the ECIS method, the wound is created in the conluent cell monolayer using a high voltage shock, and the faster the increase in imped-ance following wounding, the higher the rate of cellular migration into the wound. As an additional measure of accuracy, the change 
of impedance is recorded automatically rather than using a manual measurement. In the present study, the overexpression of 
FAPα signiicantly elevated the migration ability of SK-MES-1 cells 4 h post-wounding (n=16; SK-MES-1wt vs. SK-MES-1exp, 200.0±173.2 vs. 394.8±254.5 ohms; P=0.001; SK-MES-1pef vs. SK-MES-1exp, 228.0±282.6 vs. 394.8±254.5 ohms; P=0.017). However, the overexpression of FAPα in A549 cells had no 
effect on cell migration rate when compared with control cells 4 h post-wounding (n=16; A549wt vs. A549exp: 578.8±215.7 vs. 610.2±182.7 ohms; P=0.66; A549pef vs. A549exp, 580.2±221.8 vs. 610.2±182.7 ohms; P=0.68) (Fig. 5).
Inhibitors of SHH and PI3K inhibit the increases in cell attach-
ment and migration induced by the overexpression of FAPα. 
To examine the potential interaction of FAPα with signaling 
pathways potentially responsible for the increased adhesive and migratory properties of SK-MES-1 lung cancer cells, a panel of 
small-molecule inhibitors of a number of signaling pathways 
Figure 1. Determination of the overexpression eficiency of FAPα in lung 
cancer cells. (A) mRNA transcription of FAPα was negative in SK-MES-1wt and A549wt lung cancer cells and SK-MES-1pef and A549pef cells, but posi-tive in SK-MES-1exp and A549exp cells. (B) Western blot analysis conirmed 
the protein expression of FAPα in SK-MES-1exp and A549exp cells. FAPα, ibroblast activation protein α; wt, wild-type cells; pef, vector-transfected control cells; exp, FAPα-expressing cells.
Figure 2. Overexpression of FAPα promotes the growth of SK-MES-1 cells. 
Overexpression of FAPα had no signiicant effect on the growth rate of (A) A549 cells but signiicantly increased the growth rate of (B) SK-MES-1 cells at 3 days post-seeding (n=12). *P<0.05 vs. SK-MES-1wt and 
SK-MES-1pef. FAPα, ibroblast activation protein α; exp, FAPα-expressing cells; pef, vector-transfected control cells; wt, wild-type cells.
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were screened, including ROCK, FAK, NWASP, ERK1/2, 
PLCγ, JNK, PI3K and SHH. Using an ECIS assay (n=8 for each experiment), the effects of these inhibitors on cell attachment 
and migration were assessed. Compared with the SK-MES-1pef cells, only the inhibitors of SHH and PI3K signiicantly inhib-
ited the increased the cell attachment and motility (Fig. 6A-D) 
of the FAPα-expressing SK-MES-1exp cells.In the earlier cell function assay, the overexpression of 
FAPα in A549 cells failed to increase cellular adhesion and 
migration. The present study subsequently analyzed the effects of the above inhibitors on the attachment and motility of A549 
cells. The results showed that there was minimal difference in the attachment rate of the A549exp cells following treatment 
with the inhibitors; only the inhibitor of FAK stimulated the migration of A549exp cells, with the other inhibitors having 
no marked effect on cell migration (Fig. 6E-H).
FAPα regulates cellular functions through the PI3K/AKT 
and SHH/Gli1 pathways. To determine whether the effects 
of FAPα on the cellular functions of SK-MES-1 cells were associated with the PI3K/AKT and SHH pathways, western 
blot analysis was performed to detect the protein expression levels of total PI3K, AKT, SHH, Ptch and Gli1. As shown 
in Fig. 7, compared with the control cells, the protein levels of 
AKT and PI3K were markedly increased in the SK-MES-1exp 
cells. The protein levels of SHH and Gli1 were also increased in the SK-MES-1exp cells. By contrast, the levels of Ptch were 
similar in the SK-MES-1exp and control cells.
Discussion
FAPα is an integral membrane serine peptidase. Preliminary 
studies have shown that FAPα is expressed primarily in fetal mesenchymal tissues, stromal ibroblasts, wounded tissues, and stromal ibroblasts of malignant epithelial tumors (5-7). 
There is increasing evidence that the expression of FAPα is not conined to stromal ibroblasts but is also present in various types of epithelium-derived cancer cells (17-20). Therefore, 
the role of FAPα in cancer cells may differ from that in ibro-
blasts. Goodman et al found that the suppression of FAPα in MDA-MB-435 and MDA-MB-436 human breast cancer cell lines, which normally express FAPα, rendered these cells sensi-
tive to serum starvation (26). Cheng et al reported that mice 
inoculated with FAPα-transfected HEK293 cells were two to four times more likely to develop tumors, compared with those 
inoculated with FAPα-null control cells (27). Additionally, in an 
Figure 3. Overexpression of FAPα increases the attachment of SK-MES-1 cells to the basement substrate. (A and B) Results of the cell matrix adhesion 
assay showed that the overexpression of FAPα enhanced the adhesive properties of SK-MES-1 and A549 cells, but not signiicantly (magniication, x200). An ECIS-based attachment assay conirmed the increased attachment ability only in (C) SK-MES-1 cells, but not in (D) A549 cells over time (n=12). 
(E) The increased impedance of lung cancer cells in attachment phase of ECIS assay at 1 h after seeding. *P<0.05, SK-MES-1pef vs. SK-MES-1exp and A549pef vs. A549exp; **P<0.01, SK-MES-1exp vs. SK-MES-1wt. FAPα, ibroblast activation protein α; exp, FAPα-expressing cells; pef, vector-transfected control cells; wt, wild-type cells; ohms, unit of electrical impedance.
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in vivo mouse model, FAPα-expressing MDA-MB-231 breast 
cancer cells grew more rapidly than control cells (28). Previous studies have conirmed these early indings and suggested that 
FAPα expressed by cancer cells may serve as an oncogene. For example, it was found that FAPα promoted ovarian cancer cell proliferation, drug resistance, invasiveness and migration 
Figure 5. Overexpression of FAPα signiicantly increases the migratory ability of SK-MES-1 cells. (A and B) An ECIS-based wounding assay showed that the 
overexpression of FAPα in A549 cells had no effect on cell migration rate, compared with the control cells (n=16). (C and D) Overexpression of FAPα markedly elevated the migratory capacity of the SK-MES-1 cells at 4 h post-wounding (n=16). *P<0.05 SK-MES-1pef vs. SK-MES-1exp; SK-MES-1wt vs. SK-MES-1exp. 
FAPα, ibroblast activation protein-α; exp, FAPα-expressing cells; pef, vector-transfected control cells; wt, wild-type cells; ohms, unit of electrical impedance.
Figure 4. Overexpression of FAPα has no signiicant effect on the invasive ability of lung cancer cells. (A) Matrix gel-based invasion assay with lung cancer cells was performed 3 days post-seeding (magniication, x400). (B) Numbers of invaded cells in the SK-MES-1exp cell group were lower, compared with those in the SK-MES-1wt and SK-MES-1pef cell groups, but the differences were not signiicant. The number of invaded cells in the A549exp cell group was similar to that in the A549wt cell group, but was lower, compared with that in the A549pef cell group (n=5). *P<0.01 vs. A549exp. FAPα, ibroblast activation 
protein-α; exp, FAPα-expressing cells; pef, vector-transfected control cells; wt, wild-type cells.
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in vitro, and that the silencing of FAPα in SKOV3 cells signii-
cantly reduced tumor growth in a xenograft mouse model (29). Our previous study (25) showed that the overexpression of 
FAPα markedly increased the growth, adhesion, invasion and migration abilities of MCF-7 breast cancer cells, whereas the 
knockdown of FAPα in BT549 breast cancer cells decreased 
Figure 6. Effects of signaling pathway inhibitors on the motility of SK-MES-1 lung cancer cells. A panel of small inhibitors linked to cell motility was 
screened and only the PI3K and SHH inhibitors had substantial effects. ECIS was used to assess the effects of these inhibitors on the attachment and migration abilities of (A-D) SK-MES-1 cells and (E-H) A549 cells. The PI3K and SHH inhibitors inhibited the increased (A and C) attachment and (B and D) migration 
of SK-MES-1 cells induced by the overexpression of FAPα. In A549 cells, none of the screened inhibitors affected (E and G) cell attachment, and only FAK inhibitor appeared to stimulate (F and H) cell migration, with the other inhibitors having no marked effect on cell migration. *P>0.05. The difference between SK-MES-1exp and SK-MES-1pef cells in the absence of inhibitors was signiicant (P<0.05), but addition of inhibitors eliminated the difference. FAPα, ibro-
blast activation protein α; FAP, FAPα-expressing cells; pEF, vector-transfected control cells; ohms, unit of electrical impedance; SHH, sonic hedgehog; SHHco, control of the SHH inhibitor cyclopamine; FAK, focal adhesion kinase; ERK, extracellular signal-regulated kinase; NWASP, neural Wiskott-Aldrich syndrome protein; PI3K, phosphatidylinositol 3-kinase; PLCγ, phospholipase C-γ; ROCK, Rho-associated protein kinase; JNK, c-Jun N-terminal kinase.
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these abilities. In the present study, the overexpression of 
FAPα markedly increased the growth, adhesion and migra-tion of SK-MES-1 lung cancer cells. Therefore, these results 
suggested that the FAPα expressed by epithelial cancer cells had an oncogenic function. However, the overexpression of FAPα failed to promote the growth and motility of A549 cells 
in the present study. One reason for this may be the difference in cell type between SK-MES-1 (SCC) and A549 (AC) cells. However, Du et al reported that FAPα was expressed in AC specimens from patients with lung cancer (30). Therefore, the 
role of FAPα in lung AC cells requires clariication in further 
investigations.
The detailed mechanisms by which FAPα in epithelial 
cancer cells promote cell growth and motility remains to be fully elucidated. However, studies have revealed that FAPα has important non-enzymatic functions, which enable it to regulate the proliferation and spread of cancer cells (22,23,25). 
Huang et al found that inhibitors of FAPα did not decrease the 
growth of FAPα-expressing breast cancer cells, and that breast 
cancer cells expressing a catalytically inactive mutant of FAPα 
produced tumors rapidly in a SCID mouse model (23). Our previous study also showed that an enzymatic mutant of FAP, in which the serine catalytic triad was disrupted, markedly increased cellular growth and motility in MCF-7 breast cancer cells (25). Taken together with previous results, it appears that 
the tumorigenicity of FAPα expressed by cancer cells is not 
dependent on its enzymatic activity. There is also increasing 
evidence that FAPα is involved in the regulation of signaling pathways. In oral SCC cells, it has been reported that the 
knockdown of FAPα inactivated the PTEN/PI3K/AKT and Ras-ERK signaling pathways, resulting in the suppression of oral SCC cell proliferation, migration and invasion (24). In ovarian cancer cells, FAPα in combination with integrin α3β1 
and the uPAR signaling complex mediate cellular migration 
via the small GTPase Rac1 pathway (31). Our previous study 
showed that the FAPα-mediated promotion of cell growth 
and motility in breast cancer cells was accompanied by the upregulation of MMP2/9, phosphorylated-PI3K and phosphor-ylated-AKT (25). In addition, FAPα expressed by stromal cells 
has been reported to be involved in the regulation of signaling pathways, including RhoA (32), β-catenin (33) and ibroblast 
growth factor 1 (FGF1)/FGF receptor 3 (34). In the present study, the potential interactions of FAPα with a number of signaling pathways were analyzed, including FAK, ERK1/2, ROCK, PLCγ, JNK, NWASP, PI3K and SHH. The results showed that, for SK-MES-1 cells, treatment with PI3K or SHH inhibitors signiicantly inhibited the increase in cellular 
motility induced by the overexpression of FAPα. The results 
of the western blot analysis showed that the overexpression of 
FAPα was accompanied by increases in the protein expression levels of PI3K, AKT, SHH and Gli1, which indicated activa-
tion of the PI3K-AKT and SHH-Gli1 pathways.
There remains no direct evidence to show that FAPα is involved in the EMT process of cancer cells. However, 
Du et al analyzed the expression of transforming growth 
factor-β (TGF-β), Twist and FAPα in lung cancer tissues, and 
found that these three molecules were expressed at various 
levels in different lung cancer tissues in situ, including in 
AC tissue (30). TGF-β is a multifunctional protein and has been demonstrated to be involved in promoting EMT (35). 
Twist is a basic helix-loop-helix transcription factor and may promote EMT by downregulating E-cadherin, either directly 
or by interacting with other transcription factors (36). It has 
also been demonstrated that the SHH pathway is important in 
the development and metastasis of lung cancer. In a previous study, the expression of Gli1 was associated with the expres-
sion of EMT markers E-cadherin and β-catenin in lung SCC 
specimens. Inhibition of the SHH/Gli pathway suppressed the migration and upregulation of E-cadherin in lung SCC cells, 
whereas subsequent stimulation of the SHH pathway increased 
migration and downregulated the expression of E-cadherin in the lung SCC cells (37). In pancreatic cancer, Xu et al found that ive members of the S100 gene family, namely S100A2, S100A4, S100A6, S100A11 and S100A14, were signiicantly 
downregulated upon Gli1 knockdown. The migration of pancreatic cancer cells was also signiicantly increased in a 
Gli1 expression-dependent manner (38). These results suggest 
that FAPα may be indirectly involved in the EMT process by regulating certain signaling pathways, including SHH and 
PI3K. Further investigations are required to investigate the 
mechanisms involved.In conclusion, the present study provided evidence that 
FAPα promoted cellular growth and migration in lung SCC cells, and that the PI3K-AKT and SHH-Gli1 signaling path-
ways may be involved in the effects of FAPα on lung SCC 
cells.
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Figure 7. Detection of FAPα-mediated effects on the PI3K/AKT and SHH 
pathways in SK-MES-1 lung cancer cells using western blot analysis. Compared with control cells, the expression levels of AKT, PI3K, SHH and 
Gli1 were markedly increased in the SK-MES-1exp cells. No marked change 
in expression of Ptch was observed in the SK-MES-1exp cells. FAPα, ibro-
blast activation protein α; exp, FAPα-expressing cells; pef, vector-transfected control cells; wt, wild-type cells; PI3K, phosphatidylinositol-3-kinase; AKT, protein kinase B; SHH, sonic hedgehog; Ptch, Patched; GAPDH, glyceralde-
hyde 3-phosphate dehydrogenase.
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